PARP9 knockdown confers protection against chemoresistance and immune escape of breast cancer cells by blocking the PI3K/AKT pathway

PARP9 knockdown confers protection against chemoresistance and immune escape of breast cancer cells by blocking the PI3K/AKT pathway

Introduction This study probes the mechanism of the PARP9/PI3K/AKT/PD-L1 axis in the chemoresistance and immune escape of breast cancer cells. Material and methods The expression of related genes was detected in MCF-7/FUL cells. After MCF-7/FUL cells were treated with sh-PARP9 and/or the PI3K/AKT p...

Descripció completa

Dades bibliogràfiques
Autors principals:	Tao Hong, Dingxiang Dong, Jun Li, Lin Wang
Format:	Article
Idioma:	English
Publicat:	Termedia Publishing House 2023-03-01
Col·lecció:	Archives of Medical Science
Matèries:	breast cancer parp9 pi3k/akt pathway pd-l1 chemoresistance immune escape
Accés en línia:	https://www.archivesofmedicalscience.com/PARP9-knockdown-confers-protection-against-chemoresistance-and-immune-escape-of-breast,161444,0,2.html

Ítems similars

CNTN-1 Enhances Chemoresistance in Human Lung Adenocarcinoma Through Induction of Epithelial-Mesenchymal Transition by Targeting the PI3K/Akt Pathway
per: Ruijie Zhang, et al.
Publicat: (2017-09-01)

INPP4B inhibits glioma cell proliferation and immune escape via inhibition of the PI3K/AKT signaling pathway
per: Xiaoming Sun, et al.
Publicat: (2022-09-01)

Interstitial brachytherapy combined with PARP inhibitors in the treatment of chemoresistant recurrent epithelial ovarian cancer: A case report
per: Yuan Bian, et al.
Publicat: (2022-12-01)

Berberine Overcomes Gemcitabine-Associated Chemoresistance through Regulation of Rap1/PI3K-Akt Signaling in Pancreatic Ductal Adenocarcinoma
per: Keisuke Okuno, et al.
Publicat: (2022-09-01)

Akt isoforms differentially provide for chemoresistance in prostate cancer
per: Bo Ma, et al.
Publicat: (2022-05-01)

ZIP10 drives osteosarcoma proliferation and chemoresistance through ITGA10-mediated activation of the PI3K/AKT pathway
per: Hongyu Li, et al.
Publicat: (2021-10-01)

Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression
per: Junli Deng, et al.
Publicat: (2019-06-01)

4′-Demethylpodophyllotoxin functions as a mechanism-driven therapy by targeting the PI3K-AKT pathway in Colorectal cancer
per: Jun Liu, et al.
Publicat: (2025-01-01)

HIF-2α-dependent TGFBI promotes ovarian cancer chemoresistance by activating PI3K/Akt pathway to inhibit apoptosis and facilitate DNA repair process
per: Sijia Ma, et al.
Publicat: (2024-02-01)

Tertiary Prevention of Ovarian Cancer After PARP Inhibitor Therapy
per: ZANG Rongyu
Publicat: (2023-02-01)

Corrigendum: Regulation of microrna-497-targeting AKT2 influences tumor growth and chemoresistance to cisplatin in lung cancer
per: Lin Wang, et al.
Publicat: (2022-09-01)

Regulation of MicroRNA-497-Targeting AKT2 Influences Tumor Growth and Chemoresistance to Cisplatin in Lung Cancer
per: Lin Wang, et al.
Publicat: (2020-09-01)

Aurora-A Induces Chemoresistance Through Activation of the AKT/mTOR Pathway in Endometrial Cancer
per: Jun Wu, et al.
Publicat: (2019-05-01)

PARP9 exacerbates apoptosis and neuroinflammation via the PI3K pathway in the thalamus and hippocampus and cognitive decline after cortical infarction
per: Mengshi Liao, et al.
Publicat: (2025-02-01)

Knockdown of SNORA47 Inhibits the Tumorigenesis of NSCLC via Mediation of PI3K/Akt Signaling Pathway
per: Huiqing Yu, et al.
Publicat: (2021-03-01)

Silencing Glypican-1 enhances the antitumor effects of Pictilisib via downregulating PI3K/Akt/ERK signaling in chemo-resistant esophageal adenocarcinoma
per: Akshay Pratap, et al.
Publicat: (2023-12-01)

Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors
per: Charles-André Philip, et al.
Publicat: (2017-09-01)

Exploring role of 5hmC as potential marker of chemoresistance
per: Suhas S. Kharat, et al.
Publicat: (2020-11-01)

Uev1A promotes breast cancer cell survival and chemoresistance through the AKT-FOXO1-BIM pathway
per: Zhaojia Wu, et al.
Publicat: (2019-12-01)

Regulation of ferroptosis by PI3K/Akt signaling pathway: a promising therapeutic axis in cancer
per: Hua Su, et al.
Publicat: (2024-03-01)

SRPX2 boosts pancreatic cancer chemoresistance by activating PI3K/AKT axis
per: Gao Zhenyuan, et al.
Publicat: (2020-10-01)

Depletion of PARP10 inhibits the growth and metastatic potential of oral squamous cell carcinoma
per: Zihui Zhou, et al.
Publicat: (2022-10-01)

Getting the Akt Together: Guiding Intracellular Akt Activity by PI3K
per: Ivan Yudushkin
Publicat: (2019-02-01)

Double Insurance for OC: miRNA-Mediated Platinum Resistance and Immune Escape
per: Xueqin Zou, et al.
Publicat: (2021-04-01)

PCSK9 promotes the progression and metastasis of colon cancer cells through regulation of EMT and PI3K/AKT signaling in tumor cells and phenotypic polarization of macrophages
per: Lu Wang, et al.
Publicat: (2022-10-01)

Knockdown of CCNB2 inhibits the tumorigenesis of gastric cancer by regulation of the PI3K/Akt pathway
per: Ming Hu, et al.
Publicat: (2025-02-01)

Evodiamine inhibits programmed cell death ligand 1 expression via the PI3K/AKT signaling pathway to regulate antitumor immunity in melanoma
per: Jiamin Li, et al.
Publicat: (2025-02-01)

The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer
per: Liying Ma, et al.
Publicat: (2020-10-01)

PI3K/AKT Pathway and Brain Malformations
per: Gavin B. Rice, et al.
Publicat: (2015-07-01)

Silencing of PARP2 Blocks Autophagic Degradation
per: Laura Jankó, et al.
Publicat: (2020-02-01)

Prospects for combining immune checkpoint blockade with PARP inhibition
per: Anping Li, et al.
Publicat: (2019-09-01)

Editorial: New strategies to tackle chemoresistance in cancer
per: Carmela De Marco, et al.
Publicat: (2022-10-01)

IFIT3 accelerates the progression of head and neck squamous cell carcinoma by targeting PD-L1 to activate PI3K/AKT signaling pathway
per: Peng Liu, et al.
Publicat: (2024-01-01)

The Upregulation of IL-1β Induced by Cisplatin Triggers PI3K/AKT/MMP9 Pathway in Pericytes Mediating the Leakage of the Blood Labyrinth Barrier
per: Yu M, et al.
Publicat: (2025-01-01)

Cancer-Associated Fibroblasts Promote the Upregulation of PD-L1 Expression Through Akt Phosphorylation in Colorectal Cancer
per: Yang Gao, et al.
Publicat: (2021-11-01)

Different regulation of PARP1, PARP2, PARP3 and TRPM2 genes expression in acute myeloid leukemia cells
per: Paulina Gil-Kulik, et al.
Publicat: (2020-05-01)

Patient Derived Organoids Confirm That PI3K/AKT Signalling Is an Escape Pathway for Radioresistance and a Target for Therapy in Rectal Cancer
per: Kasun Wanigasooriya, et al.
Publicat: (2022-07-01)

Immune‐independent acquired resistance to PD‐L1 antibody initiated by PD‐L1 upregulation via PI3K/AKT signaling can be reversed by anlotinib
per: Yuan Gao, et al.
Publicat: (2023-07-01)

Knockdown of RASD1 improves MASLD progression by inhibiting the PI3K/AKT/mTOR pathway
per: Guifang Zeng, et al.
Publicat: (2024-12-01)

Knockdown of TFRC suppressed the progression of nasopharyngeal carcinoma by downregulating the PI3K/Akt/mTOR pathway
per: Guofei Feng, et al.
Publicat: (2023-08-01)